Comparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment.
AuthorsMemon, Adeel R
Butler, Joseph S
O'Riordan, Michael V
Dimitrov, Borislav D
Harty, James A
AffiliationDepartment of Trauma and Orthopaedics, Cork University Hospital, Cork, Ireland. firstname.lastname@example.org
Bone Diseases, Metabolic
Intercellular Signaling Peptides and Proteins
MetadataShow full item record
CitationComparison of serum Dkk1 (Dickkopf-1) and bone mineral density in patients on bisphosphonate treatment vs no treatment., 16 (1):118-24 J Clin Densitom
JournalJournal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
AbstractComplex pathways affect bone metabolism at the cellular level, and a balance between osteoblast and osteoclast activity is critical to bone remodeling. One of the major pathways affecting bone metabolism is Wnt/β-catenin signaling, and its disturbances lead to a wide range of bone abnormalities. An important antagonist of this pathway is Dickkopf-1 (Dkk1). Higher Dkk1 levels have been associated with increased bone loss due to inhibition of Wnt pathway. Currently, bisphosphonates are the most commonly used agents to treat primary osteoporotic patients. This study demonstrates the effect of bisphosphonates on Dkk1 levels and its correlation with bone mineral density (BMD). Eighty patients with low BMD were recruited and divided into 2 groups of 40 each (bisphosphonate treatment group and control group). The mean Dkk1 level in the treatment group was significantly reduced to 2358.18 vs 3749.80 pg/mL in the control group (p<0.001). Pearson correlation coefficient showed negative correlation between Dkk1 and BMD at lumbar spine (r=-0.55) and femoral neck in the control group; however, no such correlation was found in the treatment group (r=-0.05). Hence, bisphosphonate therapy leads to reduction in Dkk1 levels, but it does not correlate with BMD in such patients.
- The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density.
- Authors: Butler JS, Murray DW, Hurson CJ, O'Brien J, Doran PP, O'Byrne JM
- Issue date: 2011 Mar
- The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women.
- Authors: Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML
- Issue date: 2013 Sep
- Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.
- Authors: Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G
- Issue date: 2012 Jun
- Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients.
- Authors: Wang N, Xue P, Wu X, Ma J, Wang Y, Li Y
- Issue date: 2018 Feb
- High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
- Authors: Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E
- Issue date: 2012 Nov